Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury
During aortic surgery, interruption of spinal cord blood flow might cause spinal cord ischemia-reperfusion injury (IRI). The incidence of spinal cord IRI after aortic surgery is up to 28%, and patients with spinal cord IRI might suffer from postoperative paraplegia or paraparesis. Spinal cord IRI in...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/701970 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553279208292352 |
|---|---|
| author | Ping Zhu Jia-xin Li Masayuki Fujino Jian Zhuang Xiao-Kang Li |
| author_facet | Ping Zhu Jia-xin Li Masayuki Fujino Jian Zhuang Xiao-Kang Li |
| author_sort | Ping Zhu |
| collection | DOAJ |
| description | During aortic surgery, interruption of spinal cord blood flow might cause spinal cord ischemia-reperfusion injury (IRI). The incidence of spinal cord IRI after aortic surgery is up to 28%, and patients with spinal cord IRI might suffer from postoperative paraplegia or paraparesis. Spinal cord IRI includes two phases. The immediate spinal cord injury is related to acute ischemia. And the delayed spinal cord injury involves both ischemic cellular death and reperfusion injury. Inflammation is a subsequent event of spinal cord ischemia and possibly a major contributor to spinal cord IRI. However, the development of inflammatory mediators is incompletely demonstrated. And treatments available for inflammation in spinal cord IRI are insufficient. Improved understanding about spinal cord IRI and the development of inflammatory cells and cytokines in this process will provide novel therapeutic strategies for spinal cord IRI. Inflammatory cytokines (e.g., TNF-α and IL-1) may play an important role in spinal cord IRI. For treatment of several intractable autoimmune diseases (e.g., rheumatoid arthritis), where inflammatory cytokines are involved in disease progression, anti-inflammatory cytokine antagonist is now available. Hence, there is great potential of anti-inflammatory cytokine antagonist for therapeutic use of spinal cord IRI. We here review the mediators and several possibilities of treatment in spinal cord IRI. |
| format | Article |
| id | doaj-art-a143f292856c4336902f9c2bf5f48e86 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-a143f292856c4336902f9c2bf5f48e862025-02-03T05:54:29ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/701970701970Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion InjuryPing Zhu0Jia-xin Li1Masayuki Fujino2Jian Zhuang3Xiao-Kang Li4Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510100, ChinaGuangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510100, ChinaNational Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, JapanGuangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou 510100, ChinaNational Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, JapanDuring aortic surgery, interruption of spinal cord blood flow might cause spinal cord ischemia-reperfusion injury (IRI). The incidence of spinal cord IRI after aortic surgery is up to 28%, and patients with spinal cord IRI might suffer from postoperative paraplegia or paraparesis. Spinal cord IRI includes two phases. The immediate spinal cord injury is related to acute ischemia. And the delayed spinal cord injury involves both ischemic cellular death and reperfusion injury. Inflammation is a subsequent event of spinal cord ischemia and possibly a major contributor to spinal cord IRI. However, the development of inflammatory mediators is incompletely demonstrated. And treatments available for inflammation in spinal cord IRI are insufficient. Improved understanding about spinal cord IRI and the development of inflammatory cells and cytokines in this process will provide novel therapeutic strategies for spinal cord IRI. Inflammatory cytokines (e.g., TNF-α and IL-1) may play an important role in spinal cord IRI. For treatment of several intractable autoimmune diseases (e.g., rheumatoid arthritis), where inflammatory cytokines are involved in disease progression, anti-inflammatory cytokine antagonist is now available. Hence, there is great potential of anti-inflammatory cytokine antagonist for therapeutic use of spinal cord IRI. We here review the mediators and several possibilities of treatment in spinal cord IRI.http://dx.doi.org/10.1155/2013/701970 |
| spellingShingle | Ping Zhu Jia-xin Li Masayuki Fujino Jian Zhuang Xiao-Kang Li Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury Mediators of Inflammation |
| title | Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury |
| title_full | Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury |
| title_fullStr | Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury |
| title_full_unstemmed | Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury |
| title_short | Development and Treatments of Inflammatory Cells and Cytokines in Spinal Cord Ischemia-Reperfusion Injury |
| title_sort | development and treatments of inflammatory cells and cytokines in spinal cord ischemia reperfusion injury |
| url | http://dx.doi.org/10.1155/2013/701970 |
| work_keys_str_mv | AT pingzhu developmentandtreatmentsofinflammatorycellsandcytokinesinspinalcordischemiareperfusioninjury AT jiaxinli developmentandtreatmentsofinflammatorycellsandcytokinesinspinalcordischemiareperfusioninjury AT masayukifujino developmentandtreatmentsofinflammatorycellsandcytokinesinspinalcordischemiareperfusioninjury AT jianzhuang developmentandtreatmentsofinflammatorycellsandcytokinesinspinalcordischemiareperfusioninjury AT xiaokangli developmentandtreatmentsofinflammatorycellsandcytokinesinspinalcordischemiareperfusioninjury |